HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine(University of Tokyo)(HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine(University of Tokyo))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病

在研适应症-

非在研适应症

胰腺继发性恶性肿瘤

原研机构

University of Tokyo

在研机构-

非在研机构

Fukushima Medical University

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine(University of Tokyo) 相关的临床试验

NCT00677612 / Terminated临床1/2期

Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Combination With Tegafur/Uracil/Folinate in Treating Patients With Refractory Colorectal Cancer

The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201 restricted epitope peptides VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with Tegafur/Uracil/Folinate chemotherapy.

开始日期2008-05-01

申办/合作机构

University of Tokyo

[+1]

NCT00681577 / Completed临床1/2期

Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Refractory Gastric Cancer

The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptides URLC10, KOC1, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.

开始日期2008-05-01

申办/合作机构

University of Tokyo

[+1]

NCT00681252 / Completed临床1/2期

Phase I/II Study of Multiple-Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*0201 in Treating Patients With Refractory Gastric Cancer

The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201 restricted epitope peptides URLC10, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.

开始日期2008-05-01

申办/合作机构

University of Tokyo

[+1]

100 项与 HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine(University of Tokyo) 相关的临床结果

登录后查看更多信息

100 项与 HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine(University of Tokyo) 相关的转化医学

登录后查看更多信息

100 项与 HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine(University of Tokyo) 相关的专利（医药）

登录后查看更多信息

1

项与 HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine(University of Tokyo) 相关的文献（医药）

2004-08-01·The Journal of Immunology2区 · 医学

Absence of Immunodominant Anti-Gag p17 (SL9) Responses among Gag CTL-Positive, HIV-Uninfected Vaccine Recipients Expressing the HLA-A*0201 Allele

2区 · 医学

Article

作者: Koup, Richard A. ; Ferrari, Guido ; Neal, Wesley ; Buchbinder, Susan ; Tartaglia, Jim ; Edwards, Bradley H. ; McElrath, M. Juliana ; Weinhold, Kent J. ; Ottinger, Janet ; Goepfert, Paul ; Jones, Anizsa M. ; Betts, Michael R.

AbstractAccording to a number of previous reports, control of HIV replication in humans appears to be linked to the presence of anti-HIV-1 Gag-specific CD8 responses. During the chronic phase of HIV-1 infection, up to 75% of the HIV-infected individuals who express the histocompatibility leukocyte Ag (HLA)-A*0201 recognize the Gag p17 SLYNTVATL (aa residues 77–85) epitope (SL9). However, the role of the anti-SL9 CD8 CTL in controlling HIV-1 infection remains controversial. In this study we determined whether the pattern of SL9 immunodominance in uninfected, HLA-A*0201 HIV vaccine recipients is similar to that seen in chronically HIV-infected subjects. The presence of anti-SL9 responses was determined using a panel of highly sensitive cellular immunoassays, including peptide:MHC tetramer binding, IFN-γ ELISPOT, and cytokine flow cytometry. Thirteen HLA-A*0201 vaccinees with documented anti-Gag CD8 CTL reactivities were tested, and none had a detectable anti-SL9 response. These findings strongly suggest that the pattern of SL9 epitope immunodominance previously reported among chronically infected, HLA-A*0201-positive patients is not recapitulated in noninfected recipients of Gag-containing canarypox-based candidate vaccines and may be influenced by the relative immunogenicity of these constructs.

100 项与 HLA-A*0201 Restricted Antiangiogenic Peptide Vaccine(University of Tokyo) 相关的药物交易

登录后查看更多信息